ClinicalTrials.gg
RecruitingNCT06598891Updated Oct 10, 2024

PAS Balance Training for Parkinson Disease (PD)

An interventional study of Weight shift training and APA feedback and Paired associative stimulation in PD - Parkinson's Disease, sponsored by Chang Gung University. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Chang Gung University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Parkinson Disease by Chang Gung University — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · Chang Gung University.

Planned enrollment
5th of 12
60 · median 58
Started
2024
with 3 others
No phase
12 of 12
5 open now
Registered
11th of 12
by date

Among the 12 studies in Parkinson Disease by Chang Gung University, this one is the 5th largest by planned enrollment, is one of 4 that started in 2024, is one of 12 with no phase, and was the 11th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 12 studies in Parkinson Disease by Chang Gung University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Parkinson Disease by Chang Gung University, or all of them as a file.
02

Study summary

Gait initiation (GI) difficulty is a common problem in individuals with Parkinson's disease (PD), often linked to impaired anticipatory postural adjustments (APA). Currently, there are no targeted rehabilitation programs designed specifically for GI-related APA in PD patients. Research has shown that while motor learning deficits are common in PD, explicit learning is better preserved than implicit learning. Therefore, a GI-related APA training system using an explicit learning model could be particularly effective for this population.

During motor learning, long-term potentiation (LTP) increases the excitability of the primary motor cortex. Paired associative stimulation (PAS) has been demonstrated to induce LTP-like changes in the motor cortex, making it a potential priming method to enhance motor learning. However, the priming effect of PAS targeted at leg muscles and the motor cortex on motor learning related to GI-APA has not been previously studied.

The objectives of this study are:

  1. To investigate the effects of explicit and implicit training on GI-related APA.
  2. To evaluate the priming effect of PAS on GI-related APA training and the associated plasticity changes in the motor cortex.
03

Conditions studied

  • PD - Parkinson's Disease

Browse trials for

Keywords

  • Gait Initiation
  • Paired associative stimulation (PAS)
  • Balance training
  • Motor learning
  • Anticipatory postural adjustment (APA)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Parkinson disease.

Exclusion criteria

Exclusion Criteria:

  • Musculoskeletal injuries on legs
  • Osteoporosis.
  • Any peripheral or central nervous system injury or disease patients.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    PD APA training group

    Weight shift training and APA feedback.

    Procedure: Weight shift training and APA feedback

  • Experimental
    PD PAS group

    Using PAS to regulate brain plasticity

    Procedure: Paired associative stimulation

Interventions

  • ProcedureWeight shift training and APA feedback

    Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.

    Also known as: APA training

  • ProcedurePaired associative stimulation

    Use TMS combine ES to stimulate TA nerve and M1 cortical

    Also known as: PAS training

06

What researchers measure

Primary outcomes

  1. Balance Performance

    Measured by the duration the stance or stand can be maintained. Unit:second(s)

    Time frame: Baseline, 4 weeks and 8 weeks

  2. COP Path Length in Balance Tasks

    The total distance traveled by the COP over a specified period. Longer path lengths can indicate increased effort to maintain balance or greater instability.

    Time frame: Baseline, 4 weeks and 8 weeks

  3. COP Displacement in Balance Tasks

    Measures of COP movement in the anterior-posterior (AP) and medial-lateral (ML) directions, offering insights into the directional tendencies of balance control. Unit:millimeter(mm)

    Time frame: Baseline, 4 weeks and 8 weeks

  4. Motor Evoked Potentials (MEPs)

    MEPs are the electrical responses recorded from muscles following stimulation of the motor cortex. They reflect the efficiency of neural transmission from the cortex to the muscle. Unit:millivolts (mV)

    Time frame: Baseline, 4 weeks and 8 weeks

  5. Intracortical Facilitation (ICF)

    ICF is measured by applying a pair of TMS pulses with a short interval (e.g., 8-15 ms) where the first (subthreshold) pulse is followed by a second (suprathreshold) pulse, leading to an increased amplitude of the MEP.

    Time frame: Baseline, 4 weeks and 8 weeks

  6. Intracortical Inhibition (ICI)

    ICI is measured similarly to ICF but with a shorter inter-stimulus interval (e.g., 1-5 ms), resulting in a suppressed MEP amplitude. This suppression reflects inhibitory processes within the cortex.

    Time frame: Baseline, 4 weeks and 8 weeks

  7. Walking Speed

    The time taken by participants to walk a standardized distance, typically expressed in centimeters per second (cm/s).

    Time frame: Baseline, 4 weeks and 8 weeks

  8. Step Length

    The linear distance between the two ankles, typically expressed in centimeter(cm).

    Time frame: Baseline, 4 weeks and 8 weeks

  9. Step Time

    The duration taken for one complete step, measuring from foot-off of one foot to the next foot-off of the same foot, usually expressed in seconds.

    Time frame: Baseline, 4 weeks and 8 weeks

Secondary outcomes

  1. COP Velocity in Balance Tasks

    The speed at which the COP moves, calculated over the duration of the balance task. Higher velocities may reflect more dynamic balance adjustments or instability. Unit:millimeter per second(mm/s)

    Time frame: Baseline, 4 weeks and 8 weeks

  2. COP Area in Balance Tasks

    The area covered by the COP trajectory during the balance task, providing an estimate of the sway envelope. A larger area might indicate poorer balance control. Unit:square millimeter(mm\^2)

    Time frame: Baseline, 4 weeks and 8 weeks

  3. Double Support Time

    The portion of the gait cycle where both feet are in contact with the ground, indicating the transition phase between steps, expressed as a percentage of the gait cycle or in seconds.

    Time frame: Baseline, 4 weeks and 8 weeks

  4. Single Support Time

    The duration within the gait cycle when only one foot is in contact with the ground, typically measured in seconds or as a percentage of the total gait cycle.

    Time frame: Baseline, 4 weeks and 8 weeks

  5. Swing Time

    The portion of the gait cycle where the foot is not in contact with the ground, moving forward to the next step. It is usually expressed as a percentage of the total gait cycle or in seconds.

    Time frame: Baseline, 4 weeks and 8 weeks

  6. Stance Time

    The portion of the gait cycle when the foot is in contact with the ground, supporting body weight. It's typically expressed as a percentage of the total gait cycle or in seconds

    Time frame: Baseline, 4 weeks and 8 weeks

  7. Cadence

    The number of steps an individual takes per minute, providing an overview of gait speed and rhythm, , expressed as steps per minute.

    Time frame: Baseline, 4 weeks and 8 weeks

Other outcomes

  1. Total UPDRS-III Score

    The Unified Parkinson's Disease Rating Scale (UPDRS) Part III, also known as the UPDRS-III or the Motor Examination, is a critical component of the UPDRS used to assess the motor symptoms of Parkinson's disease (PD). To provide a comprehensive assessment of motor function in individuals with Parkinson's disease, covering aspects such as bradykinesia (slowness of movement), rigidity, tremors, and postural instability. The UPDRS-III consists of 14 items, each rated on a scale from 0 (normal) to 4 (severe), with a total possible score range from 0 to 108. Higher scores indicate greater motor impairment.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2026, 19 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 19 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Sep 19, 2024
StartActual
Oct 9, 2024
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06598891
Lead sponsor
Chang Gung University
Responsible party
Ya-Ju Chang (Professor, Chang Gung University) — Principal investigator
First posted
Sep 19, 2024
Start date
Oct 9, 2024
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Oct 10, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion